Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates

Virology

Volumn 251, Issue 1, 1998, Pages 28-37

  Hevey, Michael ^a   Negley, Diane ^a   Pushko, Peter ^a   Smith, Jonathan ^a   Schmaljohn, Alan ^a  

^a National Biodefense Analysis and Countermeasures Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HEMORRHAGIC FEVER; IMMUNIZATION; MARBURG VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINE PRODUCTION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS GENE;

ALPHAVIRUS; ANIMALIA; CAVIA; EQUIDAE; LAKE VICTORIA MARBURGVIRUS; MACACA; PRIMATES; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 0032506208     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9367     Document Type: Article

References (28)

1. Belanov E. F., Muntianov V. P., Kriuk V. D., Sokolov A. V., Bormotov N. I., P'Iankov O. V., Sergeev A. N. Survival of Marburg virus infectivity on contaminated surfaces and in aerosols. Vopr. Virusol. 41:1996;32-34.
2. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 1998.
3. Caley I. J., Betts M. R., Irlbeck D. M., Davis N. L., Swanstrom R., Frelinger J. A., Johnston R. E. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71:1997;3031-3038.
4. Connolly B. M., Steele K. E., Davis K. J., Geisbert T. W., Kell W. M., Jaax N. K., Jahrling P. B. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 1998.
5. Feldmann H., Klenk H. D. Marburg and Ebola viruses. Adv. Virus Res. 47:1996;1-52.
6. Feldmann H., Nichol S. T., Klenk H.-D., Peters C. J., Sanchez A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology. 199:1994;469-473.
7. Feldmann H., Will C., Schikore M., Slenczka W., Klenk H. D. Glycosylation and oligomerization of the spike protein of Marburg virus. Virology. 182:1991;353-356.
8. Frolov V. G., Gusev Iu M. Stability of Marburg virus to lyophilization process and subsequent storage at different temperatures. Vopr. Virusol. 41:1996;275-277.
9. Gilligan K. J., Geisbert J. B., Jahrling P. B., Anderson K. Assessment of protective immunity conferred by recombinant vaccinia viruses to guinea pigs challenged with ebola virus. Vaccines 97. 1997;Cold Spring Harbor Press, Cold Spring Harbor.
10. Hevey M., Negley D., Geisbert J., Jahrling P., Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 239:1997;206-216.
11. Ignat'ev G. M., Agafonov A. P., Strel'tsova M. A., Kuz'min V. A., Mainagasheva G. I., Spirin G. V., Chernyi N. B. A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus. Vopr. Virusol. 36:1991;421-423.
12. Ignat'ev G. M., Agafonov A. P., Streltsova M. A., Kashentseva E. A. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J. Biotechnol. 44:1996;111-118.
13. Johnson E., Jaax N., White J., Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76:1995;227-236.
14. Johnson K. M., Lange J. V., Webb P. A., Murphy F. A. Isolation and partial characterization of a new virus causing acute hemorrhagic fever in Zaire. Lancet. 1:1977;569-571.
15. Kiley M. P., Bowen E. T., Eddy G. A., Isaacson M., Johnson K. M., McCormick J. B., Murphy F. A., Pattyn S. R., Peters D., Prozesky O. W., Regnery R. L., Simpson D. I., Slenczka W., Sureau P., van der Groen G., Webb P. A., Wulff H. Filoviridae: A taxonomic home for Marburg and Ebola viruses? Intervirology. 18:1982;24-32.
16. Lupton H. W., Lambert R. D., Bumgardner D. L., Moe J. B., Eddy G. A. Inactivated vaccine for Ebola virus efficacious in guinea pig model [letter]. Lancet. 2:1980;1294-1295.
17. Martini G. A., Siegert R. Marburg Virus Disease. 1971;Springer-Verlag, Berlin.
18. Pattyn S., van der Groen G., Courteille G., Jacob W., Piot P. Isolation of Marburg-like virus from a case of hemorrhagic fever in Zaire. Lancet. 1:1977;573-574.
19. Pushko P., Parker M., Geisberg J. B., Negley D., Schmaljohn A., Jahrling P. B., Smith J. F., Sanchez A. Venezuelan equine encephalitis virus replicon vector: Immunogenicity studies with Ebola NP, and GP genes in guinea pigs. Brown F., Burton D., Doherty P., Mekalanos J., Norrby E. Vaccines 97. 1997a;Cold Spring Harbor Press, Cold Spring Harbor.
20. Pushko P., Parker M., Ludwig G. V., Davis N. L., Johnston R. E., Smith J. F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 239:1997b;389-401.
21. Schmaljohn A. L., Johnson E. D., Dalrymple J. M., Cole G. A. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature. 297:1982;70-72.
22. Schmaljohn A. L., Li D., Negley D. L., Bressler D. S., Turell M. J., Korch G. W., Ascher M. S., Schmaljohn C. S. Isolation and initial characterization of a newfound hantavirus from California. Virology. 206:1995;963-972.
23. Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
24. Smith D. H., Johnson B. K., Isaacson M., Swanapoel R., Johnson K. M., Killey M., Bagshawe A., Siongok T., Keruga W. K. Marburg-virus disease in Kenya. Lancet. 1:1982;816-820.
25. VanderZanden L., Bray M., Fuller D., Roberts T., Custer D., Spik K., Jahrling P., Huggins J., Schmaljohn A., Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 246:1998;134-144.
26. Volchkov V. E., Feldmann H., Volchkova V. A., Klenk H-D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. USA. 95:1998;5762-5767.
27. Xu L., Sanchez A., Yang Z., Zaki S. R., Nabel E. G., Nichol S. T., Nabel G. J. Immunization for Ebola virus infection. Nat. Med. 4:1998;37-42.
28. Zhou X., Berglund P., Zhao H., Liljestrom P., Jondal M. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc. Natl. Acad. Sci. USA. 92:1995;3009-3013.